Maël Heiblig

Publications

Article dans une revue (62)

Genetic alterations and measurable residual disease in core binding factor acute myeloid leukemia Loïc Vasseur,Matthieu Duchmann,Nicolas Duployez,Emmanuel Raffoux,Céline Berthonet al. Leukemia, 2026, ⟨10.1038/s41375-026-02900-x⟩ Article dans une revue hal-05579447v1
Efficacy of erythroid‐stimulating agent and luspatercept in VEXAS syndrome: A multicenter retrospective study by the FRENVEX group Maël Heiblig,Vincent Jachiet,Jérôme Hadjadj,Lin Pierre Zhao,Thibault Comontet al. HemaSphere, 2025, 9 (6), pp.e70156. ⟨10.1002/hem3.70156⟩ Article dans une revue hal-05395410v1
Intermediate-Dose Cytarabine as Postinduction AML Therapy Mathilde Hunault-Berger,Cécile Pautas,Sarah Bertoli,Pierre-Yves Dumas,Emmanuel Raffouxet al. NEJM Evidence, 2025, 4 (7), pp.EVIDoa2400326. ⟨10.1056/evidoa2400326⟩ Article dans une revue hal-05162195v1
Therapy-related core binding factor Acute Myeloid Leukemia – a Study of the french acute leukemia intergroup Mathilde Chanut,Loïc Vasseur,Matthieu Duchmann,Pierre Hirsch,Céline Berthonet al. Blood, 2025, 146 (Supplement 1), pp.37-37. ⟨10.1182/blood-2025-37⟩ Article dans une revue hal-05413719v1
Neurological manifestations in patients with VEXAS syndrome Charlotte Bert-Marcaz,Étienne Fortanier,Antoine Briantais,Benoit Faucher,Rim Bourguibaet al. Journal of Neurology, 2025, 272 (2), pp.181. ⟨10.1007/s00415-025-12902-x⟩ Article dans une revue hal-05253512v1
Comparison of induction with arsenic trioxide or chemotherapy in a real-world cohort of patients with high-risk acute promyelocytic leukemia Delphine Lebon,Audrey da Rocha,Bruno Cassinat,Maël Heiblig,Sarah Bertoliet al. Leukemia, 2025, 39 (8), pp.1865-1870. ⟨10.1038/s41375-025-02663-x⟩ Article dans une revue hal-05131491v1
Induction chemotherapy with a single anthracycline-containing cycle in younger adults with newly diagnosed AML – the french backbone intergroup (BIG)-1 study on behalf of the filo, ALFA, and SFGM-TC study groups Christian Recher,Cecile Pautas,Sarah Bertoli,Pierre-Yves Dumas,Emmanuel Raffouxet al. Blood, 2025, 146 (Supplement 1), pp.43-43. ⟨10.1182/blood-2025-43⟩ Article dans une revue hal-05413202v1
Impact of midostaurin in younger AML patients intensively treated with high-dose anthracycline Pierre-Yves Dumas,Mathieu Leclerc,Mathilde Hunault,Emmanuelle Tavernier,Cecile Pautaset al. Blood, 2025, 146 (Supplement 1), pp.1682-1682. ⟨10.1182/blood-2025-1682⟩ Article dans une revue hal-05413706v1
Efficacy and safety of azacitidine for VEXAS syndrome: a large-scale retrospective study from the FRENVEX group Vincent Jachiet,Olivier Kosmider,Maxime Beydon,Jerome Hadjadj,Lin-Pierre Zhaoet al. Blood, 2025, 146 (12), pp.1450-1461. ⟨10.1182/blood.2024028133⟩ Article dans une revue hal-05079306v1
Inflammatory disorders in IDH‐mutated myeloid neoplasms: Characteristics and response to IDH inhibitors Romain Stammler,Peter Chen,Orianne Debeaupuis,Lin‐pierre Zhao,Mirabelle Ruyer‐thompsonet al. HemaSphere, 2025, 9 (11), pp.e70256. ⟨10.1002/hem3.70256⟩ Article dans une revue hal-05547858v1
Correction: Neurological manifestations in patients with VEXAS syndrome Charlotte Bert-Marcaz,Étienne Fortanier,Antoine Briantais,Benoit Faucher,Rim Bourguibaet al. Journal of Neurology, 2025, 272 (6), pp.401. ⟨10.1007/s00415-025-13047-7⟩ Article dans une revue hal-05253508v1
Ivosidenib in refractory or relapsed IDH1-mutated Acute Myeloid Leukemia patients in real life settings: The ivoobs observational study from the french AML intergroup ALFA/filo Mael Heiblig,Pierre Peterlin,Stéphane Morisset,Pierre-Yves Dumas,Marie Sebertet al. Blood, 2025, 146 (Supplement 1), pp.3455-3455. ⟨10.1182/blood-2025-3455⟩ Article dans une revue hal-05413650v1
Real life study of ivosidenib in either monotherapy or combined with azacytidine for first line mutant IDH1 AML: A study from the french AML intergroup ALFA/filo Pierre Peterlin,Mael Heiblig,Stéphane Morisset,Sarah Bertoli,Marie Sebertet al. Blood, 2025, 146 (Supplement 1), pp.1658-1658. ⟨10.1182/blood-2025-1658⟩ Article dans une revue hal-05413216v1
Metabolism and therapeutic response in acute myeloid leukemia with IDH1/2 mutations Ludovic Gabellier,Enzo Bosetta,Maël Heiblig,Jean-Emmanuel Sarry Trends in Cancer, 2025, 11 (5), pp.475-490. ⟨10.1016/j.trecan.2025.01.011⟩ Article dans une revue hal-05565072v1
Comprehensive mutational profiling and clinical outcome of adults AML with NUP98 rearrangement Benoit Ducourneau,Arnaud Pages,Stéphanie Struski,Matthieu Decamp,Emmanuel Raffouxet al. Blood, 2025, 146 (Supplement 1), pp.7002-7002. ⟨10.1182/blood-2025-7002⟩ Article dans une revue hal-05413751v1
Indications and contraindications to platelet‐rich plasma injections in musculoskeletal diseases in case of infectious, oncological and haematological comorbidities: A 2025 formal consensus from the GRIIP (International Research Group on Platelet Injections) Florent Eymard,Karine Louati,Éric Noel,Redouane Abouqal,Philippe Adamet al. Knee Surgery, Sports Traumatology, Arthroscopy, 2025, 33 (6), pp.2293-2306. ⟨10.1002/ksa.12682⟩ Article dans une revue hal-05336422v1
Allogeneic Hematopoietic Cell Transplantation for VEXAS Syndrome: Results of a Multicenter Study of the EBMT. Carmelo Gurnari,Linda Koster,Laurien Baaij,Mael Heiblig,Ibrahim Yakoub-Aghaet al. Blood Advances, 2024, Blood Advances, 8, pp.1444-1448. ⟨10.1182/bloodadvances.2023012478⟩ Article dans une revue hal-04672729v1
Nonischemic Cardiac Manifestations in VEXAS Syndrome Marie Robert,Alexis Mathian,Valentin Lacombe,Hervé Lobbes,Léopold Adélaïdeet al. JAMA Network Open, 2024, 7 (12), pp.e2450251. ⟨10.1001/jamanetworkopen.2024.50251⟩ Article dans une revue hal-04888717v1
Efficacy and safety of targeted therapies in VEXAS syndrome: retrospective study from the FRENVEX Jerome Hadjadj,Yann Nguyen,Dalila Mouloudj,Rim Bourguiba,Mael Heibliget al. Annals of the Rheumatic Diseases, 2024, 83 (10), pp.1358-1367. ⟨10.1136/ard-2024-225640⟩ Article dans une revue hal-05253516v1
Efficacy and safety of mammalian target of rapamycin inhibitors in systemic mastocytosis: A nationwide French pilot study. Josquin Moraly,Julien Rossignol,Claire Rouzaud,Thomas Gabas,Hassiba Bouktitet al. American Journal of Hematology, 2024, American Journal of Hematology, 99, pp.1095-1102. ⟨10.1002/ajh.27323⟩ Article dans une revue hal-04691823v2
Deep Learning‐Based Blood Abnormalities Detection as a Tool for VEXAS Syndrome Screening Cédric de Almeida Braga,Maxence Bauvais,Pierre Sujobert,Maël Heiblig,Maxime Jullienet al. International Journal of Laboratory Hematology, 2024, ⟨10.1111/ijlh.14368⟩ Article dans une revue hal-04778186v1
Serious infections in patients with VEXAS syndrome: data from the French VEXAS registry Benjamin de Valence,Marion Delaune,Yann Nguyen,Vincent Jachiet,Mael Heibliget al. Annals of the Rheumatic Diseases, 2024, 83 (3), pp.372-381. ⟨10.1136/ard-2023-224819⟩ Article dans une revue hal-04888392v1
Serious infections in patients with VEXAS syndrome: data from the French VEXAS registry Benjamin de Valence,Marion Delaune,Yann Nguyen,Vincent Jachiet,Mael Heibliget al. Annals of the Rheumatic Diseases, 2024, 83 (3), pp.372-381. ⟨10.1136/ard-2023-224819⟩ Article dans une revue hal-05253517v1
Efficacy and safety of targeted therapies in VEXAS syndrome: retrospective study from the FRENVEX Jerome Hadjadj,Yann Nguyen,Dalila Mouloudj,Rim Bourguiba,Mael Heibliget al. Annals of the Rheumatic Diseases, 2024, pp.ard-2024-225640. ⟨10.1136/ard-2024-225640⟩ Article dans une revue hal-04711359v1
Human myeloid differentiation by BMP4 signaling through the VDR pathway in acute myeloid leukemia Florence Zylbersztejn,Iryna Byelinska,Sandrine Jeanpierre,Léa Barral,Kevin Geistlichet al. Cell Death Discovery, 2024, 10, ⟨10.1038/s41420-024-02090-4⟩ Article dans une revue hal-04675664v1
Comparison of prognostic scores according to WHO classification in 170 patients with advanced mastocytosis and C‐finding treated with midostaurin Maël Heiblig,Clément Gourguechon,Philippe Guilpain,Cristina Bulai-Livideanu,Stéphane Bareteet al. American Journal of Hematology, 2024, 99 (11), pp.2127-2139. ⟨10.1002/ajh.27478⟩ Article dans une revue inserm-04902870v1
Histological characterization of liver involvement in systemic mastocytosis. Julien Rossignol,Danielle Canioni,Achille Aouba,Cristina Bulai-Livideanu,Stéphane Bareteet al. Liver International, 2024, Liver International, 44, pp.1680-1688. ⟨10.1111/liv.15913⟩ Article dans une revue hal-04685730v2
Deep Learning Based Blood Abnormalities Detection As a Tool for Vexas Syndrome Screening Cedric de Almeida Braga,Maxence Bauvais,Pierre Sujobert,Mael Heiblig,Maxime Jullienet al. Blood, 2023, 142 (Supplement 1), pp.3648-3648. ⟨10.1182/blood-2023-186874⟩ Article dans une revue hal-04456433v1
C/EBPα Confers Dependence to Fatty Acid Anabolic Pathways and Vulnerability to Lipid Oxidative Stress–Induced Ferroptosis in FLT3 -Mutant Leukemia Marie Sabatier,Rudy Birsen,Laura Lauture,Sarah Mouche,Paolo Angelinoet al. Cancer Discovery, 2023, 13 (7), pp.1720-1747. ⟨10.1158/2159-8290.CD-22-0411⟩ Article dans une revue hal-04166110v1
Impact of Arsenic Trioxide in the Treatment of Higher Risk Acute Promyelocytic Leukemia Audrey da Rocha,Bruno Cassinat,Mael Heiblig,Christian Recher,Sarah Bertoliet al. Blood, 2023, 142 (Supplement 1), pp.1471-1471. ⟨10.1182/blood-2023-174446⟩ Article dans une revue hal-04355510v1
LSC17 score complements genetics and measurable residual disease in acute myeloid leukemia: an ALFA study Loic Vasseur,Laurène Fenwarth,Jérôme Lambert,Stéphane de Botton,Martin Figeacet al. Blood Advances, 2023, 7 (15), pp.4024-4034. ⟨10.1182/bloodadvances.2023010155⟩ Article dans une revue hal-04106615v1
Use of tamibarotene, a potent and selective RARα agonist, in combination with azacitidine in patients with relapsed and refractory AML with RARA gene overexpression Eytan Stein,Stephane de Botton,Thomas Cluzeau,Arnaud Pigneux,Jane Liesveldet al. Leukemia & lymphoma, 2023, pp.1-10. ⟨10.1080/10428194.2023.2243356⟩ Article dans une revue hal-04182855v1
From vacuoles to VEXAS Maël Heiblig,Pierre Sujobert Rheumatology, 2023, 62 (12), pp.3780-3781. ⟨10.1093/rheumatology/kead392⟩ Article dans une revue hal-04906677v1
Gemtuzumab Ozogamicin for Patients with Newly Diagnosed CD33 Positive Acute Myeloid Leukemia: Results from a French Retrospective Observational Study Juliette Lambert,Emmanuel Raffoux,Delphine Lebon,Thorsten Braun,Mael Heibliget al. Blood, 2023, 142 (Supplement 1), pp.2893-2893. ⟨10.1182/blood-2023-179575⟩ Article dans une revue hal-04355381v1
Clinical and pathological features of cutaneous manifestations in VEXAS syndrome: A multicenter retrospective study of 59 cases Ève Zakine,Loula Papageorgiou,Rim Bourguiba,Arsène Mekinian,Benjamin Terrieret al. Journal of The American Academy of Dermatology, 2023, 88 (4), pp.917-920. ⟨10.1016/j.jaad.2022.10.052⟩ Article dans une revue hal-04193759v1
Pathophysiologic implications of elevated prevalence of hereditary alpha-tryptasemia in all mastocytosis subtypes Laura Polivka,Marine Madrange,Cristina Bulai-Livideanu,Stéphane Barete,Thomas Ballulet al. Journal of Allergy and Clinical Immunology, 2023, ⟨10.1016/j.jaci.2023.08.015⟩ Article dans une revue hal-04339470v1
Serious infections in patients with VEXAS syndrome: data from the French VEXAS registry. Benjamin de Valence,Marion Delaune,Yann Nguyen,Vincent Jachiet,Mael Heibliget al. Annals of the Rheumatic Diseases, 2023, Annals of the Rheumatic Diseases, ⟨10.1136/ard-2023-224819⟩ Article dans une revue hal-04519630v1
Gilteritinib activity in refractory or relapsed FLT3-mutated acute myeloid leukemia patients previously treated by intensive chemotherapy and midostaurin: a study from the French AML Intergroup ALFA/FILO Pierre-Yves Dumas,Emmanuel Raffoux,Emilie Bérard,Sarah Bertoli,Marie-Anne Hospitalet al. Leukemia, 2023, 37 (1), pp.91-101. ⟨10.1038/s41375-022-01742-7⟩ Article dans une revue hal-04244552v1
Impact on Outcome of Minimal Residual Disease after Hematopoietic Stem Cell Transplantation with Fludarabine, Amsacrine, and Cytosine Arabinoside-Busulfan Conditioning: A Retrospective Monocentric Study Grégoire Le Meur,Adriana Plesa,Marie-Virginie Larcher,Gaëlle Fossard,Fiorenza Barracoet al. Transplantation and Cellular Therapy, 2023, 29 (1), pp.38.e1-38.e9. ⟨10.1016/j.jtct.2022.09.003⟩ Article dans une revue hal-04906736v1
Chronic myelomonocytic leukemia transdifferentiation landscape: From histiocytosis to blastic plasmacytoid dendritic cell neoplasm Gabriel Antherieu,Marie Donzel,Brigitte Balme,Alexandra Traverse-Glehen,Maël Heiblig American Journal of Hematology, 2023, 98 (8), pp.1343-1345. ⟨10.1002/ajh.26876⟩ Article dans une revue hal-04906261v1
VEXAS: where do we stand 2 years later? Pierre Sujobert,Maël Heiblig,Yvan Jamilloux Current Opinion in Hematology, 2023, 30 (2), pp.64-69. ⟨10.1097/MOH.0000000000000750⟩ Article dans une revue hal-04906810v1
Mutational Profile and Dynamics of PPM1D -Mutant Clones in the Spectrum of Myeloid Disorders Jean Pegliasco,David Fandrei,Florence Pasquier,Nathalie Ibrahim,Maria Kfouryet al. Blood, 2023, 142 (Supplement 1), pp.4064-4064. ⟨10.1182/blood-2023-189428⟩ Article dans une revue hal-04356640v1
Ruxolitinib is more effective than other JAK inhibitors to treat VEXAS syndrome: a retrospective multicenter study Maël Heiblig,Marcela Ferrada,Matthew Koster,Thomas Barba,Mathieu Gerfaud-Valentinet al. Blood, 2022, 140 (8), pp.927-931. ⟨10.1182/blood.2022016642⟩ Article dans une revue hal-04907677v1
Retrospective analysis of hematopoietic cell transplantation for blastic plasmacytoid dendritic cell neoplasm: conditioning intensity matters Peter-Martin Bruch,Sascha Dietrich,Herve Finel,Ariane Boumendil,Hildegard Greinixet al. Leukemia, 2022, 37 (2), pp.465-472. ⟨10.1038/s41375-022-01782-z⟩ Article dans une revue hal-04922926v1
Class I/Class II HLA Evolutionary Divergence Ratio Is an Independent Marker Associated With Disease-Free and Overall Survival After Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia Anne-Marie Daull,Valérie Dubois,Hélène Labussière-Wallet,Fabienne Venet,Fiorenza Barracoet al. Frontiers in Immunology, 2022, 13, pp.841470. ⟨10.3389/fimmu.2022.841470⟩ Article dans une revue inserm-04010303v1
Molecular heterogeneity and measurable residual disease of rare NPM1 mutations in acute myeloid leukemia: a nationwide experience from the GBMHM study group Elise Fournier,Maël Heiblig,Christine Lespinasse,Pascale Flandrin-Gresta,Antoine Geayet al. Leukemia, 2022, 36 (5), pp.1390-1400. ⟨10.1038/s41375-022-01534-z⟩ Article dans une revue hal-04907143v1
Diagnosis of acute promyelocytic leukemia based on routine biological parameters using machine learning Estelle Cheli,Simon Chevalier,Olivier Kosmider,Marion Eveillard,Nicolas Chapuiset al. Haematologica, 2022, 107 (6), pp.1466-1469. ⟨10.3324/haematol.2022.280406⟩ Article dans une revue hal-04907070v1
Pleuropulmonary manifestations of VEXAS syndrome Raphael Borie,Marie-Pierre Debray,Alexis F. Guedon,Arsène Mekinian,Louis Terriouet al. Chest, 2022, Chest, 163 (3), pp.575-585. ⟨10.1016/j.chest.2022.10.011⟩ Article dans une revue hal-04498358v1
Antibody-based therapy for acute myeloid leukemia: a review of phase 2 and 3 trials Xavier Thomas,Mohamed Elhamri,Alexandre Deloire,Maël Heiblig Expert Opinion on Emerging Drugs, 2022, 27 (2), pp.169-185. ⟨10.1080/14728214.2022.2094365⟩ Article dans une revue hal-04907717v1
Allogenic Stem Cell Transplantation Abrogates Negative Impact on Outcome of AML Patients with KMT2A Partial Tandem Duplication Gabriel Antherieu,Audrey Bidet,Sarah Huet,Sandrine Hayette,Marina Migeonet al. Cancers, 2021, 13 (9), pp.2272. ⟨10.3390/cancers13092272⟩ Article dans une revue hal-04908304v1
Toward a pathophysiology inspired treatment of VEXAS syndrome Maël Heiblig,Bhavisha Patel,Emma Groarke,Estelle Bourbon,Pierre Sujobert Seminars in Hematology, 2021, 58 (4), pp.239-246. ⟨10.1053/j.seminhematol.2021.09.001⟩ Article dans une revue hal-04908739v1
How to Transform an Exceptional Case Report Into a Therapy: Following the Frog Out of the Box Maël Heiblig,Vincent Alcazer,Adriana Plesa,Hélène Labussière-Wallet,Pierre Sujobert HemaSphere, 2021, 5 (9), pp.e629. ⟨10.1097/HS9.0000000000000629⟩ Article dans une revue hal-04908718v1
Azacitidine for patients with Vacuoles, E1 Enzyme, X-linked, Autoinflammatory, Somatic syndrome (VEXAS) and myelodysplastic syndrome: data from the French VEXAS registry Thibault Comont,Mael Heiblig,Etienne Riviere,Louis Terriou,Julien Rossignolet al. British Journal of Haematology, 2021, British Journal of Haematology, -, ⟨10.1111/bjh.17893⟩ Article dans une revue hal-04481451v1
Chronic T cell receptor stimulation unmasks NK receptor signaling in peripheral T cell lymphomas via epigenetic reprogramming Sylvain Carras,Dimitri Chartoire,Sylvain Mareschal,Maël Heiblig,Antoine Marçaiset al. The Journal of clinical investigation, 2021, 131 (13), pp.e139675. ⟨10.1172/jci139675⟩ Article dans une revue inserm-03280949v1
The Impact of DNMT3A Status on NPM1 MRD Predictive Value and Survival in Elderly AML Patients Treated Intensively Mael Heiblig,Nicolas Duployez,Alice Marceau,Delphine Lebon,Laure Goursaudet al. Cancers, 2021, 13 (9), ⟨10.3390/cancers13092156⟩ Article dans une revue hal-03606391v1
Therapeutic options in VEXAS syndrome: insights from a retrospective series Estelle Bourbon,Maël Heiblig,Mathieu Gerfaud Valentin,Thomas Barba,Cécile-Audrey Durelet al. Blood, 2021, 137 (26), pp.3682-3684. ⟨10.1182/blood.2020010177⟩ Article dans une revue hal-04908402v1
Performances of Targeted RNA Sequencing for the Analysis of Fusion Transcripts, Gene Mutation, and Expression in Hematological Malignancies Sandrine Hayette,Béatrice Grange,Maxime Vallee,Claire Bardel,Sarah Huetet al. HemaSphere, 2021, 5 (2), pp.e522. ⟨10.1097/HS9.0000000000000522⟩ Article dans une revue hal-04382990v1
Initial Results from a Biomarker-Directed Phase 2 Trial of SY-1425, a Potent and Selective RAR alpha Agonist, in Combination with Azacitidine in Relapsed/Refractory Acute Myeloid Leukemia Eytan M. Stein,Stephane de Botton,Thomas Cluzeau,Arnaud Pigneux,Jane L. Liesveldet al. Blood, 2020, 136 (1), ⟨10.1182/blood-2020-134602⟩ Article dans une revue hal-03606393v1
Impact of DNMT3a Status on Post Induction NPM1 MRD Predictive Value on Survival in Elderly AML Patients Treated Intensively Maël Heiblig,Nicolas Duployez,Alice Marceau,Delphine Lebon,Laure Goursaudet al. Blood, 2020, 136 (1), ⟨10.1182/blood-2020-141890⟩ Article dans une revue hal-03606389v1
Prognostic Value of Genetic Alterations in Elderly Patients with Acute Myeloid Leukemia: A Single Institution Experience Maël Heiblig,Hélène Labussière-Wallet,Franck Emmanuel Nicolini,Mauricette Michallet,Sandrine Hayetteet al. Cancers, 2019, 11 (4), pp.570. ⟨10.3390/cancers11040570⟩ Article dans une revue hal-04908088v1
Ponatinib evaluation and safety in real-life chronic myelogenous leukemia patients failing more than two tyrosine kinase inhibitors: the PEARL observational study Maël Heiblig,Delphine Rea,Marie-Lorraine Chrétien,Aude Charbonnier,Philippe Rousselotet al. Experimental Hematology, 2018, 67, pp.41 - 48. ⟨10.1016/j.exphem.2018.08.006⟩ Article dans une revue hal-01927788v1
The development of agents targeting the BCR-ABL tyrosine kinase as Philadelphia chromosome-positive acute lymphoblastic leukemia treatment Xavier Thomas,Maël Heiblig Expert Opinion on Drug Discovery, 2016, 11 (11), pp.1061-1070. ⟨10.1080/17460441.2016.1227318⟩ Article dans une revue hal-01796194v1

Communication dans un congrès (1)

Secondary-type acute myeloid leukemia is associated with a higher risk of invasive fungal infection during intensive induction therapy. a correlative study on the ALFA 0702 trial. Jean-Eudes Fahrner,Mauricette Michallet,Laurene Fenwarth,Mohamad Sobh,Stéphane Morissetet al. 67th ASH annual meeting, Dec 2025, Orlando (FL), United States. pp.994-994, ⟨10.1182/blood-2025-994⟩ Communication dans un congrès hal-05413683v1

Thèse (1)

Les mutations d'IDH2 dans la leucémie aigue myéloïde confèrent une sensibilité spécifique à l'inhibition du métabolisme des acides aminés branchés (BCAA) Maël Heiblig Cancer. Université Paris-Saclay, 2022. Français. ⟨NNT : 2022UPASL018⟩ Thèse tel-04108390v1